Immunoadjuvant activity of oral Lactobacillus casei: influence of dose on the secretory immune response and protective capacity in intestinal infections - PubMed (original) (raw)

Immunoadjuvant activity of oral Lactobacillus casei: influence of dose on the secretory immune response and protective capacity in intestinal infections

G Perdigón et al. J Dairy Res. 1991 Nov.

Abstract

Lactobacilli, often used as effectors of host functions, could play an important role in maintaining human health by controlling other intestinal microorganisms capable of producing harmful effects. Using an experimental model, we studied the effect of different oral doses of Lactobacillus casei on the secretory IgA response and the protective capacity of the microorganism in preventing intestinal infections. The optimization of the protective dose of Lb. casei by previous feeding and the use of the lactobacillus as an immunological way to control enteric infections were investigated. We found that conventional mice were protected against infection with Salmonella typhimurium and Escherichia coli by previous feeding for 2 consecutive days with a daily Lb. casei dose of 1.2 x 10(9) cfu/mouse. Previous feeding for 7 d proved less effective, and feeding for 5 d afforded no protection at all. We were also able to demonstrate that the protective effect of Lb. casei against Sal. typhimurium and Esch. coli was connected mainly with the high level of IgA antipathogen antibodies present in intestinal secretions. beta-Glucuronidase (EC 3.2.1.31) and beta-galactosidase (EC 3.2.1.23) activities, measured both in the intestinal fluid and histological samples, showed a marked increase in intestinal inflammatory response on day 5 of feeding. These results show that Lb. casei plays an important role in the prevention of enteric infections, a low dose being enough for protection against intestinal infections by increasing IgA secretion into the intestinal lumen, thus providing adequate defences for the mucosal surface. A previously administered dose of this magnitude could therefore be used as an oral adjuvant in preventing enteric infections.

PubMed Disclaimer

Cited by

Potential uses of probiotics in clinical practice.
Reid G, Jass J, Sebulsky MT, McCormick JK. Reid G, et al. Clin Microbiol Rev. 2003 Oct;16(4):658-72. doi: 10.1128/CMR.16.4.658-672.2003. Clin Microbiol Rev. 2003. PMID: 14557292 Free PMC article. Review.
In situ fabrication of radiopaque microcapsules for oral delivery and real-time gastrointestinal tracking of Bifidobacterium.
Fang Z, Jiang R, Zhang L, Wu Y, Zhao X, Zhao L, Li J, Zou S, Zhang M, Du F. Fang Z, et al. Int J Nanomedicine. 2018 Jul 12;13:4093-4105. doi: 10.2147/IJN.S145837. eCollection 2018. Int J Nanomedicine. 2018. PMID: 30034235 Free PMC article.
Lactobacillus rhamnosus GR-1 enhances NF-kappaB activation in Escherichia coli-stimulated urinary bladder cells through TLR4.
Karlsson M, Scherbak N, Reid G, Jass J. Karlsson M, et al. BMC Microbiol. 2012 Jan 22;12:15. doi: 10.1186/1471-2180-12-15. BMC Microbiol. 2012. PMID: 22264349 Free PMC article.
Challenges and Strategies for Developing Recombinant Vaccines against Leptospirosis: Role of Expression Platforms and Adjuvants in Achieving Protective Efficacy.
de Oliveira NR, Santos FDS, Dos Santos VAC, Maia MAC, Oliveira TL, Dellagostin OA. de Oliveira NR, et al. Pathogens. 2023 May 31;12(6):787. doi: 10.3390/pathogens12060787. Pathogens. 2023. PMID: 37375478 Free PMC article. Review.
Deciphering the Potential of Probiotics in Vaccines.
Xu C, Aqib AI, Fatima M, Muneer S, Zaheer T, Peng S, Ibrahim EH, Li K. Xu C, et al. Vaccines (Basel). 2024 Jun 26;12(7):711. doi: 10.3390/vaccines12070711. Vaccines (Basel). 2024. PMID: 39066349 Free PMC article. Review.

Immunoadjuvant activity of oral Lactobacillus casei: influence of dose on the secretory immune response and protective capacity in intestinal infections - PubMed (original) (raw)